SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    M. Fisher, Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective, Diabetes, Obesity and Metabolism, 2015, 17, 1
  2. 2
    Paul L. McCormack, Exenatide Twice Daily: A Review of Its Use in the Management of Patients with Type 2 Diabetes Mellitus, Drugs, 2014, 74, 3, 325

    CrossRef

  3. 3
    Baptist Gallwitz, Extra-pancreatic effects of incretin-based therapies, Endocrine, 2014, 47, 2, 360

    CrossRef

  4. 4
    Samuel S. Grossman, Pathophysiological and Pharmacological Rationale for the Use of Exenatide Once Weekly in Patients with Type 2 Diabetes, Advances in Therapy, 2014, 31, 3, 247

    CrossRef

  5. 5
    Agostino Consoli, Gloria Formoso, Potential side effects to GLP-1 agonists: understanding their safety and tolerability, Expert Opinion on Drug Safety, 2014, 1

    CrossRef

  6. You have free access to this content6
    J. Seufert, B. Gallwitz, The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems, Diabetes, Obesity and Metabolism, 2014, 16, 8
  7. 7
    Borje Darpo, Nenad Sarapa, Christine Garnett, Charles Benson, Corina Dota, Georg Ferber, Venkateswar Jarugula, Lars Johannesen, James Keirns, Kevin Krudys, Catherine Ortemann-Renon, Steve Riley, Danise Rogers-Subramaniam, Norman Stockbridge, The IQ-CSRC Prospective Clinical Phase 1 Study: “Can Early QT Assessment Using Exposure Response Analysis Replace the Thorough QT Study?”, Annals of Noninvasive Electrocardiology, 2014, 19, 1
  8. 8
    John R Petrie, The cardiovascular safety of incretin-based therapies: a review of the evidence, Cardiovascular Diabetology, 2013, 12, 1, 130

    CrossRef